hypoxic ischemic encephalopathy hie pipeline insight

DelveInsight’s, “Hypoxic Ischemic Encephalopathy Pipeline Insight, 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Hypoxic Ischemic Encephalopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hypoxic Ischemic Encephalopathy Understanding

Hypoxic Ischemic Encephalopathy Overview

Hypoxic-Ischemic Encephalopathy is a serious neonatal brain injury caused by a reduction in oxygen supply and blood flow to the brain before, during, or shortly after birth. It is one of the most severe complications affecting term infants and is associated with a high risk of mortality and long-term neurological disabilities, including cerebral palsy, epilepsy, and cognitive impairment. The underlying pathology of HIE results from impaired cerebral perfusion and oxygen delivery, leading to primary and secondary energy failure, neuronal injury, inflammation, and cell death.

Hypoxic-Ischemic Encephalopathy is primarily caused by a reduction in oxygen supply and blood flow to the infant’s brain before, during, or shortly after birth. Common causes include perinatal asphyxia resulting from obstetric complications such as umbilical cord prolapse, uterine rupture, placental abruption, placenta previa, maternal hypotension, breech presentation, and shoulder dystocia. These events impair cerebral perfusion and oxygen delivery, leading to brain injury and subsequent neurological dysfunction.

The pathophysiology of Hypoxic-Ischemic Encephalopathy begins with reduced oxygen and blood flow to the brain, leading to primary energy failure, depletion of cellular ATP, and neuronal dysfunction. Following reperfusion, a secondary phase of injury occurs, characterized by excitotoxicity, oxidative stress, inflammation, calcium influx, and apoptosis, which further damage brain tissue. This evolving cascade of cellular injury contributes significantly to the neurological deficits associated with HIE.

Diagnosis of Hypoxic-Ischemic Encephalopathy is based on a combination of clinical history, neurological examination, and supportive laboratory and imaging findings. Key indicators include evidence of perinatal asphyxia, low Apgar scores, metabolic acidosis, altered consciousness, abnormal muscle tone, and seizures. Neuroimaging, particularly MRI, along with electroencephalography (EEG), helps assess the extent of brain injury and supports diagnosis and prognosis.

Treatment of Hypoxic-Ischemic Encephalopathy focuses on limiting ongoing brain injury and providing supportive care. Therapeutic hypothermia has become the standard neuroprotective intervention for eligible infants, helping to reduce neuronal damage by slowing metabolic and inflammatory processes. Additional management includes maintaining adequate oxygenation and perfusion, controlling seizures, and monitoring for multi-organ dysfunction to improve neurological outcomes.

"Hypoxic Ischemic Encephalopathy Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypoxic Ischemic Encephalopathy pipeline landscape is provided which includes the disease overview and Hypoxic Ischemic Encephalopathy treatment guidelines. The assessment part of the report embraces, in depth Hypoxic Ischemic Encephalopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypoxic Ischemic Encephalopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Hypoxic Ischemic Encephalopathy Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hypoxic Ischemic Encephalopathy R&D. The therapies under development are focused on novel approaches to treat/improve Hypoxic Ischemic Encephalopathy. 

Hypoxic Ischemic Encephalopathy Emerging Drugs Analysis

This segment of the Hypoxic Ischemic Encephalopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypoxic Ischemic Encephalopathy Emerging Drugs

RLS-0071: ReAlta Life Sciences, Inc.

RLS-0071 (pegtarazimod) is a novel peptide therapy being investigated for neonatal hypoxic-ischemic encephalopathy (HIE). RLS-0071 is a dual-action complement inhibitor and anti-inflammatory peptide designed to reduce the secondary brain injury that occurs after a hypoxic-ischemic event. Its mechanism of action involves inhibiting the classical complement pathway and suppressing inflammatory mediators such as myeloperoxidase (MPO) and reactive oxygen species (ROS), thereby reducing neuroinflammation, oxidative stress, and immune-cell–mediated tissue damage. By targeting these key drivers of reperfusion injury, RLS-0071 aims to protect neurons and improve neurological outcomes in infants with HIE. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Hypoxic Ischemic Encephalopathy.

Further product details are provided in the report……..

Hypoxic Ischemic Encephalopathy Drug Therapeutic Assessment

This segment of the report provides insights about the different Hypoxic Ischemic Encephalopathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Hypoxic Ischemic Encephalopathy Players in Hypoxic Ischemic Encephalopathy

There are approx. 4+ key companies which are developing the therapies Hypoxic Ischemic Encephalopathy. The companies which have their Hypoxic Ischemic Encephalopathy drug candidates in the most advanced stage, i.e. Phase II include, ReAlta Life Sciences, Inc. and others.

Hypoxic Ischemic Encephalopathy Clinical Trial Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Hypoxic Ischemic Encephalopathy Drug Route of Administration

Hypoxic Ischemic Encephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Hypoxic Ischemic Encephalopathy Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Hypoxic Ischemic Encephalopathy Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypoxic Ischemic Encephalopathy Clinical Trial Activities

The Hypoxic Ischemic Encephalopathy Pipeline report provides insights into different Hypoxic Ischemic Encephalopathy Clinical Trial within phase II, I, preclinical and discovery stage. It also analyses Hypoxic Ischemic Encephalopathy therapeutic drugs key players involved in developing key drugs. 

Hypoxic Ischemic Encephalopathy Pipeline Development Activities

The Hypoxic Ischemic Encephalopathy Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypoxic Ischemic Encephalopathy drugs.

Hypoxic Ischemic Encephalopathy Report Insights

• Hypoxic Ischemic Encephalopathy Pipeline Analysis
• Hypoxic Ischemic Encephalopathy Therapeutic Assessment
• Hypoxic Ischemic Encephalopathy Unmet Needs
• Impact of Hypoxic Ischemic Encephalopathy Drugs

Hypoxic Ischemic Encephalopathy Report Assessment

• Hypoxic Ischemic Encephalopathy Pipeline Product Profiles
• Hypoxic Ischemic Encephalopathy Therapeutic Assessment
• Hypoxic Ischemic Encephalopathy Pipeline Assessment
• Hypoxic Ischemic Encephalopathy Inactive drugs assessment
• Hypoxic Ischemic Encephalopathy Market Unmet Needs

Key Questions Answered in the Hypoxic Ischemic Encephalopathy Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Hypoxic Ischemic Encephalopathy drugs?
• How many Hypoxic Ischemic Encephalopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypoxic Ischemic Encephalopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypoxic Ischemic Encephalopathy therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Hypoxic Ischemic Encephalopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Hypoxic Ischemic Encephalopathy Key Players

• ReAlta Life Sciences, Inc.
• Neuren Pharmaceuticals
• Acadia pharmaceuticals

Hypoxic Ischemic Encephalopathy Key Products

• RLS-0071
• NNZ-2591